36 results about "Appetite Suppression" patented technology

Compositions and methods for administering ketone bodies to a subject include beta-hydroxybutyrate complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

A combination therapy including both intranasal and oral solid-form preparations is described. In combination, the intranasal and oral delivery pathways provided an enhancement in appetite suppression and associated weight loss in comparison to either intranasal or oral solid-form therapy alone. It was unexpected that the observed substantial increase and increase in rate of weight loss would be observed for the combination therapy, which on average provided a nearly 12% reduction in total body weight over the three-month trial.

The invention relates to the technical field of polypeptide drugs for metabolic diseases, in particular to a glucagon-like peptide (GLP-1), a glucose-dependent insulinotropic polypeptide (GIP) and a glucagon (GCG) triple receptor agonist (protein). According to the triple receptor agonist protein provided by the technical scheme, weight reduction is achieved, meanwhile, lower side effects are shown, and drug compliance is enhanced. The triple receptor stimulant researched and developed by the technical scheme can be applied to preparation of medicines with the effects of losing weight, reducing lipid or reducing blood sugar, solves the technical problem that the existing GLP-1, GIP and GCG triple receptor stimulants are difficult to reduce side effects while reducing body weight, and breaks through the weight loss mode that the traditional medicines depend on appetite suppression; due to the unique action mechanism and good safety, a safer and more effective treatment scheme is provided for patients, and the medicine has wide market prospects and social benefits.

The application discloses application of O-acyl-alpha-hydroxy acid compounds in weight loss and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine use and functional food development. The O-acyl-alpha-hydroxy acid compounds can inhibit weight growth of high-fat diet-induced obese model mice and reduce body fat. Compared with GLP-1 receptor weight loss drugs which achieve the effect of reducing weight by inhibiting appetite, the O-acyl-alpha-hydroxy acid compounds are not dependent on appetite inhibition, and can reduce side effects such as gastrointestinal discomfort and muscle loss caused by inhibiting appetite. When combined or sequentially administered with GLP-1 drugs, the O-acyl-alpha-hydroxy acid compounds can maintain or enhance the weight loss effect while improving the side effects caused by GLP-1, and can prevent the risk of significant weight rebound after stopping GLP-1 by maintaining body weight. The application provides a safe and effective new strategy for weight loss and lipid reduction.

To provide anti-obesity agents to overcome defects of currently used anti-obesity agents, that is, as main types of the previously developed anti-obesity drugs, appetite suppressants acting on the central nervous system are drugs that control the action of neurotransmitters (for example, phentermine, mazindol, lorcaserin, fluoxetine and sibutramine) were mostly used, but the neurotransmitter modulators exert a wide range of effects on various physiological actions in addition to appetite suppression by numerous subtype receptors, so that the modulators are lacking in selectivity for each subtype and have a large disadvantage in that various side effects are accompanied in a case of long-term administration.SOLUTION: The present invention relates to uses of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof for the purpose of preventing or treating rare genetic obesity diseases, particularly rare genetic obesity diseases associated with a damaged melanocortin-4 receptor (MC4R) pathway.SELECTED DRAWING: None

The invention provides a process for preparing a plasticised superporous hydrogel material comprising subjecting initial hydrogel material to treatment with an acidic solution, an optional treatment with a monovalent metal salt solution, freeze drying and plasticisation. Optionally, the process of the invention produces moulded plasticised superporous hydrogel material bodies that have one or more through-holes formed therein. The plasticised superporous hydrogel material of the present invention may be formulated as a suitable oral dosage form for use an appetite suppressant and for use to deliver a pharmaceutical and / or nutraceutical into a human or animal body.

The present invention discloses a guarana extract – EGCG synergistic fat-burning composition, belonging to the technical field of functional foods and weight management. The composition comprises guarana extract, epigallocatechin gallate, and konjac glucomannan. By controlling the component ratio and key parameters, a dynamic gel network formed by konjac glucomannan provides in-situ protection of active ingredients and enables programmed release in the gastrointestinal tract, while constructing a multi-level appetite-suppression system with temporal continuity.The invention overcomes problems in the prior art, including poor stability, low bioavailability, and fragmented appetite regulation, and achieves synergistic effects in fat burning and intake control. It is suitable for preparing oral solid formulations, with high safety, good stability, and suitability for large-scale industrial production and commercialization.

The present application relates to the technical field of bioactive peptides, and in particular to an oat oligopeptide, preparation thereof and application thereof in preparing a product for regulating the expression of brain appetite suppressor factor. The oat oligopeptide can effectively stimulate the release of cholecystokinin (CCK) from intestinal endocrine cells, and stimulate the central nervous system through the vagus nerve pathway, thereby promoting the expression of the appetite suppressor factor pro-opiomelanocortin (POMC) in the hypothalamus. Compared with the prior art, the oat oligopeptide has the advantages of stable structure, high safety, simple preparation process (conventional enzymatic hydrolysis and chromatographic purification can achieve the preparation), easy scale production and the like. The oat oligopeptide is suitable for being used as a functional ingredient or a drug precursor to develop a related health product with the functions of regulating appetite and promoting satiety, and has a wide application prospect in the field of preparing functional products (food, medicine and the like).

A composition comprising a soy protein isolate, a soy fibre, a phospholipid, and a carbohydrate for use in the treatment or prevention of obesity, type 2 diabetes or cardiovascular disorders, wherein the composition is administered together with a first pharmaceutical composition comprising an appetite suppressant agent.

The invention relates to the technical field of medicines, in particular to combined application of semeglutide and sodium butyrate in preparation of a medicine for reducing weight. Experimental results show that when the semeglutide and the sodium butyrate are combined for use, the appetite inhibition effect can be synergistically enhanced, and the body weight and the fat weight of a mouse are remarkably reduced.

A sublingual phentermine spray composition for daytime use comprises phentermine in a pharmaceutically-acceptable carrier and a sublingual phentermine spray composition for nighttime use comprises phentermine and a sleep aid in a pharmaceutically-acceptable carrier. Sublingual administration of sublingual phentermine spray compositions in accordance with the present disclosure provides an alternative to oral administration, avoiding such side effects as daytime drowsiness and intestinal disturbances. Nighttime use compositions comprising a sleep aid such as melatonin help manage the usual insomnia experienced when using phentermine. These compositions find use in suppressing appetite, for losing weight, and for maintaining a desired personal appearance.

The present application provides a soluble dietary fiber composition, its preparation method and application. After the soluble dietary fiber composition enters the colon, the ester bond in the alanine modified pectin is rapidly degraded, part of the chlorogenic acid is released, the secretion of anorectic hormone is stimulated, the appetite is reduced, and the heat intake is reduced; the remaining amide bond network is slowly degraded, realizing the slow and continuous release of chlorogenic acid. Lutein removes free radicals generated by fat decomposition, reducing the oxidative damage of L cells. Galactomannan and alanine modified pectin-glucan modified protein-chlorogenic acid ternary complex synergize to improve the molar ratio of butyric acid / propionic acid: propionic acid enhances satiety through intestinal gluconeogenesis, and butyric acid stimulates the secretion of GLP-1 / PYY, realizing endogenous appetite suppression. Galactomannan absorbs water to form a lubricating gel, softening the stool and increasing the stool volume; the ternary complex degrades to produce short-chain fatty acids, optimizing the intestinal microenvironment and enhancing gastrointestinal peristalsis, both of which synergistically improve constipation.

Compositions and methods for administering ketone bodies to a subject include a ketone body or ketone body precursor complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

The present disclosure provides recombinantly manufactured fusion proteins comprising a GLP-1 protein fragment or an analog thereof linked to a feline Fc fragment. Embodiments include the administration of the fusion proteins to patients and their use as an appetite suppressant, for treatment of obesity, for prevention of obesity, or for treatment of other conditions associated with excess weight in cats. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The present invention provides a method for preparing a plasticized superporous hydrogel material, which comprises subjecting an initial hydrogel material to treatment with an acidic solution, optionally treatment with a monovalent metal salt solution, freeze-drying and plasticization. Optionally, the method of the present invention prepares a molded plasticized superporous hydrogel material body in which one or more through-holes are formed. The plasticized superporous hydrogel material of the present invention can be formulated into a suitable oral dosage form for appetite suppressants and for delivering drugs and / or nutraceuticals to a human or animal body.

A sublingual phentermine spray composition for daytime use comprises phentermine in a pharmaceutically-acceptable carrier and a sublingual phentermine spray composition for nighttime use comprises phentermine and a sleep aid in a pharmaceutically-acceptable carrier. Sublingual administration of sublingual phentermine spray compositions in accordance with the present disclosure provides an alternative to oral administration, avoiding such side effects as daytime drowsiness and intestinal disturbances. Nighttime use compositions comprising a sleep aid such as melatonin help manage the usual insomnia experienced when using phentermine. These compositions find use in suppressing appetite, for losing weight, and for maintaining a desired personal appearance.

Compositions and methods for administering ketone bodies to a subject include a beta-hydroxybutyrate ester of an alcohol, such as a sugar or sugar alcohol. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

A composition for use in increasing insulin secretion, appetite suppression, increasing circulating glucagon-like peptide 1 (GLP-1), reducing plasma glucose levels, or treating diabetes. The composition has a compound having the formula (I) wherein: R1 and R2 are each individually H or OH; R3 is optionally substituted C1-6 alkyl or optionally substituted carbocyclyl.

The invention discloses application of 2-hydroxy-3-methylpentanoic acid in weight reduction and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine application and functional food development. The invention provides the application of the 2-hydroxy-3-methylvaleric acid and the derivative thereof in weight loss for the first time, and the compound can inhibit weight gain of a high-fat diet induced obesity model mouse, reduce body fat and reduce the fat cell area of the high-fat diet induced obesity model mouse. Compared with a GLP-1 receptor weight-reducing drug for reducing weight by inhibiting appetite, the compound 2-hydroxy-3-methylvaleric acid and the derivative thereof do not depend on appetite inhibition, and interfere and prevent obesity by accelerating fat metabolism, so that the effect of reducing weight is achieved; and side effects such as gastrointestinal discomfort and cardiovascular risk caused by appetite intervention are avoided. The invention provides a safe and effective new strategy for reducing weight and lipid.

Disclosed herein is the use of N6-benzylaminopurine (BAP) as an appetite suppressant in animals including humans. The results of studies demonstrate the use of BAP as an appetite suppressant in animals, and the use of this common agricultural supplement for plant growth can be used to help to alleviate the ever-growing obesity pandemic afflicting modern society.

The present invention aims to provide a food (including foods for specified health uses and foods with functional claims) or pharmaceutical product containing rare sugars as an active ingredient that can be used for novel applications. [Solution] The above problem is achieved by a food composition or pharmaceutical composition containing D-allose, D-sorbose, or derivatives thereof as an active ingredient, for the prevention, improvement, or treatment of symptoms or diseases selected from the group consisting of obesity due to overeating, diabetes or elevated blood glucose levels resulting from obesity due to overeating, and hepatic fat accumulation resulting from obesity due to overeating.

The present disclosure provides recombinantly manufactured fusion proteins comprising a GLP-1 protein fragment or an analog thereof linked to a feline Fc fragment. Embodiments include the administration of the fusion proteins to patients and their use as an appetite suppressant, for treatment of obesity, for prevention of obesity, or for treatment of other conditions associated with excess weight in cats. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The invention belongs to the technical field of biological medicine, and particularly relates to application of BRP polypeptide in preparation of a medicine for treating diabetes. The invention discloses application of BRP polypeptide in preparation of a medicine for treating diabetes. The amino acid sequence of the BRP polypeptide is shown as SEQ ID NO. 1. Pancreas islet and cell experiments prove that the BRP polypeptide stimulates secretion of insulin, glucagon and GLP-1 in a dose-dependent manner and is independent of an ATP-dependent potassium channel. In obese diabetic mice induced by high fat diet, the BRP polypeptide is proved to be capable of remarkably promoting secretion of insulin and GLP-1 of the mice, the BRP polypeptide has a brand-new and direct hormone stimulation application potential in the aspect of medicines for treating metabolic diseases such as diabetes and obesity, and the BRP polypeptide is different from the prior art focusing on appetite inhibition and has a wide application prospect. Therefore, a research direction is provided for developing medicines for treating metabolic diseases such as diabetes mellitus and obesity.

The application discloses a kind of guanara extract-EGCG synergistic fat-burning slimming composition, it relates to the technical field of functional food and weight management.The composition is composed of guanara extract, epigallocatechin gallate and konjac glucomannan, by limiting the weight ratio of each component and key performance parameter, using the dynamic gel network formed by konjac glucomannan, realize the in-situ physical protection and whole digestive tract programmed release of active ingredients, and build a multi-level coherent and connected appetite suppression system.The application solves the technical problems of poor stability of active ingredients, low bioavailability and fragmented appetite regulation mechanism in the prior art, can realize the deep synergy of fat-burning and food control, can be used for preparing weight management related oral solid preparations, has high safety, is suitable for industrial large-scale production and market promotion and application.

A sublingual phentermine spray composition for daytime use comprises phentermine in a pharmaceutically-acceptable carrier and a sublingual phentermine spray composition for nighttime use comprises phentermine and a sleep aid in a pharmaceutically-acceptable carrier. Sublingual administration of sublingual phentermine spray compositions in accordance with the present disclosure provides an alternative to oral administration, avoiding such side effects as daytime drowsiness and intestinal disturbances. Nighttime use compositions comprising a sleep aid such as melatonin help manage the usual insomnia experienced when using phentermine. These compositions find use in suppressing appetite, for losing weight, and for maintaining a desired personal appearance.

The present invention relates to new compounds having appetite-suppressing effects and their uses as a drug for treating diseases and disorders, especially metabolic syndrome. In particular, the present invention relates to compounds of general formula (I) and their uses as a drug for treating diseases and disorders, especially metabolic syndrome.

The present invention relates to the delivery of a composition, preferably a pharmaceutical composition, comprising D-pinitol, D-chiro-inositol or myo-inositol, or any pharmaceutically acceptable salt thereof, for the treatment or prevention of a condition, disease or condition in a subject in need thereof in response to stimulation of a starvation receptor. In particular, for the treatment and / or prevention of conditions responsive to positive modulation (stimulation) of the starvation receptor, such as diabetes, obesity-related conditions, and most preferably for the treatment or prevention of age-related conditions or diseases, such as obesity-related conditions. Enhancing muscle viability or fragility, and treating or preventing sarcopenia, improving cognition (and / or treating or preventing diseases such as Alzheimer's disease, vascular dementia, Parkinson's disease and huntington's disease), for example by promoting appetite, inhibiting insulin secretion and reducing insulin resistance, increasing growth hormone release, by increasing net muscle mass and treating or preventing age-related hypertension.

To provide an oral composition having excellent glucagon-like peptide-1 secretion promoting action and appetite suppressing action.SOLUTION: The glucagon-like peptide-1 secretion-promoting composition contains Terminalia beryllia. The appetite suppressing composition contains Terminalia beryllia.SELECTED DRAWING: None

This invention relates to the delivery of a composition, preferably a pharmaceutical composition, comprising D-pinitol, D-Chiro inositol or myo-inositol or any pharmaceutically acceptable salt thereof, for use in the treatment or prevention of disorders, diseases or conditions responsive to the stimulation of the ghrelin receptor in a subject in need thereof. In particular, for the treatment and / or prevention of disorders responsive to the positive modulation (stimulation) of the ghrelin receptor, such as diabetes, obesity-related disorders, and, most preferably, for treating or preventing age related conditions or diseases such as by promoting appetite, inhibiting insulin secretion and lowering insulin resistance, increasing growth hormone release, enhancing muscle vitality or fragility and treating or preventing sarcopenia by increasing net muscle mass, improving cognition (and / or treating or preventing diseases such as Azlheimer's disease, vascular dementia, Parkinson's Disease, and Huntington's disease) and treating or preventing age related hypertension.

Compositions and methods for administering ketone bodies to a subject include a ketone body or ketone body precursor complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.